Although anti-vascular therapy in HCC has not achieved as satisfactory efficacy as in lung cancer and colorectal cancer, anti-VEGF therapy represented by sorafenib and lenvatinib used to be the only drug for advanced HCC treatment [5,6,23]. Here, VEGFA is linked to hepatocellular carcinoma.